These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36508878)

  • 1. Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate model.
    de Wit E; Feldmann F; Cronin J; Goldin K; Mercado-Hernandez R; Williamson BN; Meade-White K; Okumura A; Callison J; Weatherman S; Rosenke R; Avanzato VA; Lovaglio J; Scott DP; Marzi A; Feldmann H
    EBioMedicine; 2023 Jan; 87():104405. PubMed ID: 36508878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease.
    Mire CE; Geisbert JB; Agans KN; Versteeg KM; Deer DJ; Satterfield BA; Fenton KA; Geisbert TW
    Emerg Infect Dis; 2019 Jun; 25(6):1144-1152. PubMed ID: 31107231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.
    DeBuysscher BL; Scott D; Marzi A; Prescott J; Feldmann H
    Vaccine; 2014 May; 32(22):2637-44. PubMed ID: 24631094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential.
    Monath TP; Nichols R; Tussey L; Scappaticci K; Pullano TG; Whiteman MD; Vasilakis N; Rossi SL; Campos RK; Azar SR; Spratt HM; Seaton BL; Archambault WT; Costecalde YV; Moore EH; Hawks RJ; Fusco J
    PLoS Pathog; 2022 Jun; 18(6):e1010658. PubMed ID: 35759511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge.
    Yoneda M; Georges-Courbot MC; Ikeda F; Ishii M; Nagata N; Jacquot F; Raoul H; Sato H; Kai C
    PLoS One; 2013; 8(3):e58414. PubMed ID: 23516477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease.
    Woolsey C; Borisevich V; Fears AC; Agans KN; Deer DJ; Prasad AN; O'Toole R; Foster SL; Dobias NS; Geisbert JB; Fenton KA; Cross RW; Geisbert TW
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36445779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses in mice and pigs after oral vaccination with rabies virus vectored Nipah disease vaccines.
    Shuai L; Ge J; Wen Z; Wang J; Wang X; Bu Z
    Vet Microbiol; 2020 Feb; 241():108549. PubMed ID: 31928698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease.
    Monath TP; Nichols R; Feldmann F; Griffin A; Haddock E; Callison J; Meade-White K; Okumura A; Lovaglio J; Hanley PW; Clancy CS; Shaia C; Rida W; Fusco J
    Front Immunol; 2023; 14():1216225. PubMed ID: 37731485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.
    Foster SL; Woolsey C; Borisevich V; Agans KN; Prasad AN; Deer DJ; Geisbert JB; Dobias NS; Fenton KA; Cross RW; Geisbert TW
    Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2200065119. PubMed ID: 35286211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.
    Lo MK; Bird BH; Chattopadhyay A; Drew CP; Martin BE; Coleman JD; Rose JK; Nichol ST; Spiropoulou CF
    Antiviral Res; 2014 Jan; 101():26-9. PubMed ID: 24184127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates.
    Zeitlin L; Cross RW; Woolsey C; West BR; Borisevich V; Agans KN; Prasad AN; Deer DJ; Stuart L; McCavitt-Malvido M; Kim DH; Pettitt J; Crowe JE; Whaley KJ; Veesler D; Dimitrov A; Abelson DM; Geisbert TW; Broder CC
    Sci Transl Med; 2024 Apr; 16(741):eadl2055. PubMed ID: 38569014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters.
    van Doremalen N; Lambe T; Sebastian S; Bushmaker T; Fischer R; Feldmann F; Haddock E; Letko M; Avanzato VA; Rissanen I; LaCasse R; Scott D; Bowden TA; Gilbert S; Munster V
    PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007462. PubMed ID: 31170144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs.
    Kong D; Wen Z; Su H; Ge J; Chen W; Wang X; Wu C; Yang C; Chen H; Bu Z
    Virology; 2012 Oct; 432(2):327-35. PubMed ID: 22726244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A highly effective ferritin-based divalent nanoparticle vaccine shields Syrian hamsters against lethal Nipah virus.
    Yin C; Yao YF; Yang P; Liu H; Gao G; Peng Y; Chen M; Lu M; Zhang X; Guo W; Zhang Z; Hu X; Yuan Z; Shan C
    Front Immunol; 2024; 15():1387811. PubMed ID: 38911870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.
    Mire CE; Versteeg KM; Cross RW; Agans KN; Fenton KA; Whitt MA; Geisbert TW
    Virol J; 2013 Dec; 10():353. PubMed ID: 24330654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.
    Bossart KN; Rockx B; Feldmann F; Brining D; Scott D; LaCasse R; Geisbert JB; Feng YR; Chan YP; Hickey AC; Broder CC; Feldmann H; Geisbert TW
    Sci Transl Med; 2012 Aug; 4(146):146ra107. PubMed ID: 22875827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.
    van den Pol AN; Mao G; Chattopadhyay A; Rose JK; Davis JN
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8.
    Watanabe S; Yoshikawa T; Kaku Y; Kurosu T; Fukushi S; Sugimoto S; Nishisaka Y; Fuji H; Marsh G; Maeda K; Ebihara H; Morikawa S; Shimojima M; Saijo M
    PLoS Negl Trop Dis; 2023 Dec; 17(12):e0011851. PubMed ID: 38100536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
    Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
    mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third Helical Domain of the Nipah Virus Fusion Glycoprotein Modulates both Early and Late Steps in the Membrane Fusion Cascade.
    Zamora JLR; Ortega V; Johnston GP; Li J; André NM; Monreal IA; Contreras EM; Whittaker GR; Aguilar HC
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.